|Awarded On||December 05, 2012|
|Title||Clinical MR spectroscopy development of 2-hydroxyglutarate as a specific biomarker for malignant gliomas|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Changho Choi|
|Cancer Sites||Brain and Other Nervous System|
Mutation of the gene, isocitrate dehydrogenase (IDH) in over 70% of patients with grade 2 and 3 malignant gliomas and 10% of glioblastoma, has created a great deal of interest in the biology of these difficult to treat primary brain tumors. Since the mutation is not found in other brain cancers, the presence of the gene makes the diagnosis of glioma. Moreover, presence of the mutation is associated with a better prognosis for the patient. The gene is important in cell metabolism and, when mutated, leads to accumulation of an abnormal metabolite, 2hydroxyglutarate (2HG). We have developed a method to identify 2HG by a brain MR scan. Thus, tumors that are found to have 2HG by MR scan are ...